Novel Small Molecule Antiviral Agents for Treatment of SARS-CoV-2 causing COVID 19 coronavirus disease: Target Identification and Structural Optimization [Funder: MI4]
- Funded by Other Funders (Canada)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Other Funders (Canada)Principal Investigator
Cosa, GonzaloResearch Location
CanadaLead Research Institution
McGill UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Creating new drugs to treat COVID-19 could save lives. Researchers at the University of Alberta have discovered a chemical compound that prevents RSV, a respiratory virus, from being infectious. McGill chemist Dr. Gonzalo Cosa is partnering with the University of Alberta to investigate whether the compound can be adapted to stop the SARS-CoV-2 virus from being infectious, slowing the spread of the disease. If successful, this new compound could be developed into a drug that effectively treats COVID-19.